EXPRESS: Immune Effector Cell-Associated Neurotoxicity Syndrome in Hematological Malignancy Patients Treated with CAR-T Cell: A Systematic Review. (PubMed, J Investig Med) - Oct 9, 2026 - "Approximately one in four CAR-T recipients develop ICANS, with nearly one in ten experiencing severe neurotoxicity. Risk varies significantly by product, supporting the need for product-specific risk stratification, monitoring strategies, and toxicity mitigation approaches."
Journal • Review • Hematological Disorders • Hematological Malignancies • Oncology
|
|
Jasmine Cha; Jerry Qi; Kareem Latif; Mohammad Dastjerdi; Mojtaba Akhtari; Robert Niihara
|